GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth
Gilead Sciences reported Q3 2026 adjusted earnings of $2.55 per share, beating estimates. Revenues rose 6.8% to $8.3B, driven by HIV drugs and Trodelvy. HIV sales grew 18% to $6.25B, while Trodelvy sales jumped 42% to $506M. GILD raised its 2026 product sales guidance to $31-$31.3B. Cell Therapy revenues declined 18% to $355M. Shares have gained 38.2% year to date.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of Q3 beats and an increased 2026 product sales outlook, plus specific pipeline/regulatory milestones (Bixlenvo approval, planned islatravir/lenacapavir filing, Trodelvy expansion).
Market read
Guidance raise and segment-level growth drivers are likely to drive near-term positioning in Gilead and influence sentiment across large-cap biotech with HIV and oncology exposure.
What to watch
The article flags potential Medicare pricing headwinds for Biktarvy in 2028 and expects inventory normalization in Q4, which could temper longer-duration optimism.
Background
Zacks frames Gilead’s Q3 performance around HIV franchise growth (Biktarvy, Descovy, Yeztugo) and oncology expansion (Trodelvy), while cell therapy declines continue.
Ticker impact
Gilead reported Q3 2026 EPS and revenue beats and raised 2026 product sales guidance, with HIV franchise strength and Trodelvy growth driving results.
Likely upward pressure as the market reprices Gilead’s 2026 revenue trajectory higher, offset partially by weaker cell-therapy trends and margin/charge headwinds.
The article discloses a fresh earnings beat plus explicit guidance increase (product sales $31-$31.3B) and segment drivers (HIV, Trodelvy, Livdelzi), which are direct inputs to near-term valuation.
Market effects
Reinforces strength in HIV franchise and selective oncology diversification, while highlighting ongoing competitive headwinds in cell therapy.
Limited direct regional spillover beyond US large-cap biotech sentiment.
FDA and European Commission approvals mentioned can support broader investor risk appetite for global biotech pipelines.
Counterpoint
Cell therapy remains under pressure and management’s adjusted loss forecast widened, so the guidance raise may not translate into proportionate earnings upside.
Key entities
- companyGilead Sciences
Reported Q3 2026 adjusted EPS and revenue beats, raised 2026 product sales guidance, and highlighted HIV and Trodelvy growth alongside cell-therapy declines.
